Lausanne, Switzerland-based Comphya, a clinical-stage medtech company, has closed an oversubscribed Series A funding round at CHF 7.5M (approximately €8.07M).
The funding comes after positive results from a study in Australia, where patients who had robotic-assisted prostate surgery were implanted with Comphya’s CaverSTIM system.
At the 2025 American Urological Association Annual Meeting in Las Vegas, results showed that most patients maintained good erectile function after surgery without needing additional treatments. No infections or other problems were reported, claims the company.
Fund utilisation
The company will use the funds to launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval announced in January 2025.
Additionally, the capital will be used to prepare for a pivotal U.S. clinical trial planned for 2026, including regulatory and operational groundwork.
Further, the Swiss company will use the investment to expand its ongoing clinical trial in Australia, where early data have shown strong safety and efficacy signals by recruiting additional patients.
“We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with erectile dysfunction following treatment for prostate cancer,” says Pim van Wesel, CEO of Comphya.
The announcement comes a couple of months after the appointment of industry veteran Pim van Wesel as CEO in May 2025 to guide the company through its next stage of clinical growth and strategic execution.
Comphya: Neurostimulation therapy for erectile dysfunction
Led by Pim van Wesel, Comphya is a medical device company developing CaverSTIM, the first implantable device to restore erectile function in patients non-responsive to oral drugs.
At present, patients suffering from erectile dysfunction often resort to intrapenile injections or penile implants, the only available yet painful, problematic, and outdated therapies.
Founded in 2017 as a spin-off from EPFL in Lausanne, Comphya’s patented solution offers a unique and superior treatment for erectile dysfunction.
CaverSTIM: What do you need to know?
The company’s first implantable neurostimulator, CaverSTIM, is designed to restore erectile function.
This technology is primarily intended for patients who are non-responders to oral medications, such as post-prostatectomy patients.
CaverSTIM is a neurostimulation system composed of an implantable pulse generator (IPG) containing a rechargeable battery and electronics responsible for generating the electrostimulation signal.
It is connected to an array of two electrodes (with multiple individual electrodes) to be implanted in the pelvic cavity, where they will activate and restore the nerves responsible for penile erection.
The IPG is implanted subcutaneously in the lower abdomen and is remotely operated by external controllers.
The clinician controller allows the medical expert to adjust and tailor the system parameters to best suit each patient.
“With our U.S. pilot study underway and preparations beginning for a pivotal clinical trial, we’re entering an important new chapter in our development,” adds van Wesel.
